Anlotinib Plus S-1 for Patients with EGFR Mutation-Negative Advanced Squamous Cell Lung Cancer with PS Scores of 2–3 After Progression of Second-Line or Later-Line Treatment

OBJECTIVE: The study aimed to analyze the efficacy and safety of combination regimen of anlotinib and S-1 for Chinese patients with EGFR mutation-negative advanced squamous cell lung cancer (SqCLC) with poor performance status (PS,2–3) after progression of second-line or later-line chemotherapy. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Xiao-Hong, Wang, Fei, Lin, Xin-Qing, Qin, Yin-Yin, Xie, Zhan-Hong, Zhang, Jie-Xia, Ouyang, Ming, Zhou, Cheng-Zhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735716/
https://www.ncbi.nlm.nih.gov/pubmed/33328765
http://dx.doi.org/10.2147/CMAR.S278068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735716/
https://www.ncbi.nlm.nih.gov/pubmed/33328765
http://dx.doi.org/10.2147/CMAR.S278068

Ejemplares similares